# Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

> **NCT00063778** · PHASE1 · COMPLETED · sponsor: **AlphaVax, Inc.** · enrollment: 48 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** AVX101
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00063778
- **Lead sponsor:** AlphaVax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063778, "Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00063778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*